Latest news and press releases about Context Therapeutics Inc. (CNTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Price
| Price | $0.38 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.91 |
| EV / EBITDA | 0.23 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -82.06% |
| Return on Invested Capital | -126.84% |
| Return on Assets | -99.62% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLNN · CNTB · IFRX · IMA · KLRS · MGNX · ORMP
Explore sector: Healthcare · Biotechnology
More sections of CNTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks